Skip to content
Screener

Enliven Therapeutics ELVN Q3 2025 earnings

Reported November 12, 2025 · Before market open

EPS-$0.32Beat by $0.11
Revenue estimate$8.3K
EPS estimate-$0.43

Next report

Date not yet announced

Financials

Q3 2025

Income statement

See full
Operating income-$25.1M+7.3%
Net income-$20.1M+13.0%
EPS (diluted)-$0.32+33.3%

Balance sheet

See full
Cash & equivalents$101.7M+1.1%
Total debt$490.0K+476%
Total equity$476.1M+65.1%
Total assets$490.9M+60.7%

Cash flow

See full
Operating cash flow-$13.3M-8.9%
Free cash flow-$13.3M-8.7%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.21B-1.6%
Enterprise value$1.11B-1.8%

Returns & leverage

See full
Return on equity-25.4%-3.9pp
Debt / equity0×0.0×
Current ratio32.9×+15.5×

FAQ

When did Enliven Therapeutics report Q3 2025 earnings?
Enliven Therapeutics (ELVN) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Enliven Therapeutics's Q3 2025 revenue and EPS?
Enliven Therapeutics reported eps of $-0.32 for Q3 2025.
Did Enliven Therapeutics beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.43 by $0.11.
How did Enliven Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 33.3% from $-0.48.
Where can I find Enliven Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-277580) and the 10-Q periodic report (0001193125-25-277619) directly on SEC EDGAR. The filing index links above go to sec.gov.